COMMUNIQUÉS West-GlobeNewswire

Enable Injections Announces CE Certification of the enFuse® On-Body Delivery System for Use with Aspaveli® Distributed by Sobi
22/05/2026
Regulatory milestone expands access to wearable, patient-centric drug delivery for rare disease treatment across Europe CINCINNATI, May 22, 2026 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare [...]
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
22/05/2026
Base shelf prospectus is accessible on SEDAR+ NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp [...]
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
22/05/2026
SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today [...]
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand
22/05/2026
Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed GAITHERSBURG, Md., May 22, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs , Inc. (Nasdaq: AIDX) (“20/20 Biolabs” or [...]
American Shared Hospital Services Announces Annual Shareholder Meeting to be Held on June 24, 2026
22/05/2026
SAN FRANCISCO, May 22, 2026 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer [...]
Ebola Outbreak “Spreading at Alarming Speed,” WHO Warns — Growing Global Health Emergencies Highlight Rising Need for TOMI’s SteraMist Technology
22/05/2026
Recent Ebola and Hantavirus Outbreaks Underscore Increasing Institutional Demand for Advanced Disinfection Solutions Across Hospitals, Hotels, Cruise Ships, Transportation Hubs, and Public Facilities FREDERICK, Md., May [...]
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors
22/05/2026
Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech [...]
SBC Medical and BLEZ ASIA Celebrate Opening of New Aesthetic Dermatology Section at BLEZ CLINIC in Bangkok
22/05/2026
Japanese-Quality Pico Laser Treatment to Serve the Growing Thai Aesthetic Healthcare Market, with Service Launch Scheduled for June 2026 IRVINE, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings [...]
Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
22/05/2026
WALTHAM, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the William Blair [...]
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
22/05/2026
CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in [...]
China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis
22/05/2026
Not intended for UK and US media Therapy approved based on Phase Ib Beamion LUNG-1 trial data, demonstrating robust efficacy (75.7% objective response rate) in treatment-naïve patients 1 Expedited approval as an initial [...]
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
22/05/2026
Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitamig in combination [...]
STORM Therapeutics to Present Promising Phase 1 Sarcoma Data Demonstrating Activity of First‑in‑Class METTL3 Inhibitor STC‑15 at ASCO 2026
22/05/2026
Subset analysis shows early clinical activity supported by biomarker evidence of targeting cancer stem cell pathways driving tumor growth and progression CAMBRIDGE, United Kingdom, May 22, 2026 (GLOBE NEWSWIRE) -- STORM [...]
ANGEL Introduces X2 Water Filter System with Advanced Tankless 7-Stage Filtration and 99% PFAS Reduction
22/05/2026
LOS ANGELES, May 22, 2026 (GLOBE NEWSWIRE) -- ANGEL, a global water purification brand, has introduced the X2 Tankless RO Water Filter System, a compact under-sink solution designed to deliver fresh purified water while [...]
CROSSJCROSSJECT annonce le succès d’une augmentation de capital et d’une émission de bons de souscription d’actions (BSA) au profit d’investisseurs pour un montant de 15 millions d’euros
22/05/2026
Nouveaux financements immédiats pour soutenir les prochaines étapes stratégiques de la Société Renforcement des capitaux propres et amélioration de la structure financière de la Société Soutient de la poursuite des [...]
CROSSJECT announces the successful completion of an equity financing and warrant issuance for a total immediate gross amount of €15 million
22/05/2026
Provides immediate new financing to support the Company’s next strategic milestones Strengthens shareholders’ equity and improves the Company’s financial structure Supports the continuation of ZEPIZURE® regulatory [...]
Ex dividend NOK 1.00 today
22/05/2026
The shares in Vistin Pharma ASA (VISTN) will be traded ex dividend NOK 1.00 as from today, 22.05.2026.
OSE Immunotherapeutics annonce les résultats de Topline positifs de l'étude de Phase 2 TEDOVA de Tedopi® dans le cancer de l’ovaire en rechute
22/05/2026
Les résultats de Topline seront présentés par le Pr Alexandra Leary, PhD, le 30 mai 2026 au congrès annuel de l’ American Society of Clinical Oncology (ASCO) à Chicago OSE Immunotherapeutics organisera un webcast avec [...]
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
22/05/2026
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer Topline results to be presented by Alexandra Leary, MD, PhD, on May 30, 2026, at the 2026 Annual [...]

Pages